Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to: Migrasomes: A Novel Target for Cancer Treatment.

Current cancer drug targets·2026
Same author

Rural Dermatology in the Subtropics: A Cross-Sectional Study of Patterns of Dermatoses, Follow-Up Visits, and Treatment Compliance at a Rural Health Center in North India.

The American journal of tropical medicine and hygiene·2026
Same author

Youth as catalysts: A novel approach to addressing hypertension awareness and detection.

Annals of pediatric cardiology·2026
Same author

Health Insurance: Awareness and Coverage in Urban Slums of Northern India.

Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine·2026
Same author

Impact of Maternal Road Traffic Noise Exposure on Hippocampal Spatial Memory and Neurogenesis of Sprague Dawley Offspring: Therapeutic Effects of Edaravone, Melatonin, and Enriched Environments.

Central nervous system agents in medicinal chemistry·2025
Same author

An Overview of Novel Indole Scaffolds with Structural Aspects and Receptor Inhibition for Cancer Treatment.

Current topics in medicinal chemistry·2025

Related Experiment Video

Updated: Jul 8, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Combretastatin a-4 analogs as anticancer agents.

Anurag Chaudhary1, S N Pandeya, P Kumar

  • 1Dr. K.N. Modi Institute of Pharmaceutical Education and Research, Modinagar-201201, U.P., India. anurag15182@rediffmail.com

Mini Reviews in Medicinal Chemistry
|January 29, 2008
PubMed
Summary

Combretastatin A-4 (CA-4) shows strong anticancer effects by stopping cell division and blood vessel growth. This review explores the medicinal chemistry of synthesized CA-4 analogs for improved cancer treatments.

More Related Videos

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

Related Experiment Videos

Last Updated: Jul 8, 2026

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Oncology

Background:

  • Combretastatin A-4 (CA-4) is a natural product with significant antimitotic and antiangiogenic properties.
  • CA-4 has demonstrated potent antitumor activity across various preclinical cancer models.
  • The development of CA-4 analogs aims to enhance its therapeutic potential.

Purpose of the Study:

  • To compile and review the medicinal chemistry of synthesized Combretastatin A-4 analogs.
  • To provide an overview of structure-activity relationships for CA-4 derivatives.
  • To highlight the ongoing efforts in developing novel CA-4 based anticancer agents.

Main Methods:

  • Literature review of synthesized Combretastatin A-4 analogs.
  • Analysis of published data on the anticancer activity of CA-4 derivatives.
  • Summary of medicinal chemistry strategies employed in analog design.

Main Results:

  • Numerous CA-4 analogs have been synthesized and evaluated.
  • These analogs exhibit a range of antimitotic and antiangiogenic activities.
  • Structure-activity relationship studies guide the design of more potent compounds.

Conclusions:

  • CA-4 and its analogs represent a promising class of anticancer agents.
  • Medicinal chemistry efforts continue to optimize the efficacy and reduce toxicity of these compounds.
  • Further research into CA-4 analogs holds potential for new cancer therapies.